2012
DOI: 10.1016/j.ijrobp.2011.04.031
|View full text |Cite
|
Sign up to set email alerts
|

High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer in Patients at Moderate or High Risk of Biochemical Recurrence

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
50
0
6

Year Published

2013
2013
2024
2024

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 105 publications
(58 citation statements)
references
References 27 publications
2
50
0
6
Order By: Relevance
“…Other centers use HDR monotherapy and the trend is to use fewer treatments -some centers are currently investigating 1 or 2 HDR implants with no IGRT [41,42]. Our clinical experience is that brachytherapy is tolerated best and has less technical limitations for men with smaller prostate volumes and with lower urinary scores at baseline [43] whereas SABR can safely treat patients with larger prostates and worse urinary scores.…”
Section: Discussionmentioning
confidence: 99%
“…Other centers use HDR monotherapy and the trend is to use fewer treatments -some centers are currently investigating 1 or 2 HDR implants with no IGRT [41,42]. Our clinical experience is that brachytherapy is tolerated best and has less technical limitations for men with smaller prostate volumes and with lower urinary scores at baseline [43] whereas SABR can safely treat patients with larger prostates and worse urinary scores.…”
Section: Discussionmentioning
confidence: 99%
“…Hoskin et al [19] reported about early ≥Grade 3 GU and GI morbidity was 3%–7% and 0%, respectively. Late Grade 3 GU toxicity was 3%–16% with no late Grade 3 or 4 GU or GI toxicity.…”
Section: Discussionmentioning
confidence: 99%
“…The technique of HDR 192 Ir afterloading, volume-based planning at this center has been previously described (2,9). The number of interstitial needles used ranged from 10 to 23 and was dependent on the volume treated.…”
Section: Treatment Schedulementioning
confidence: 99%
“…Now, there are increasing data to suggest that HDR-BT as monotherapy is an effective option, with acceptable low rates of toxicity (2)(3)(4)(5), as a viable treatment choice for a broad spectrum of patients with low-risk to high-risk prostate cancer.…”
Section: Introductionmentioning
confidence: 99%